Výsledky vyhledávání - "Nora Sanchez"

Akademický článek

In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer

Publikováno v: Cell Reports, Vol 16, Iss 1, Pp 133-147 (2016)

Current treatment regimens for pancreatic ductal adenocarcinoma (PDAC) yield poor 5-year survival, emphasizing the critical need to identify druggable targets essential for PDAC maintenance. We developed an unbiased and in vivo target discovery appro

Externí odkaz: https://doaj.org/article/f92a64bf21474917a1f9f089f11ae0b4

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

The Rise in Divorce and Cohabitation: Is There a Link?

Autor: Perelli-Harris, Brienna, Berrington, Ann, Gassen, Nora Sánchez, Galezewska, Paulina, Holland, Jennifer A.

Publikováno v: Population and Development Review, 2017 Jun 01. 43(2), 303-329.

Externí odkaz: https://www.jstor.org/stable/26622895

Zobrazit plný text záznamu

Plný text ve formátu HTML

Supplementary Data Figure S2 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response

Somatic HLA-I LOH is associated with decreased durable clinical benefit and progression free survival in ICI-treated NSCLC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25ae8eba790bd7e6d70baa335276b460
https://doi.org/10.1158/2159-8290.22535725.v1

Zobrazit plný text záznamu

Data from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response

Neoantigen presentation arises as a result of tumor-specific mutations and is a critical component of immune surveillance that can be abrogated by somatic LOH of the human leukocyte antigen class I (HLA-I) locus. To understand the role of HLA-I LOH i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7e82d91644d24da5d493cb0d66e86e71
https://doi.org/10.1158/2159-8290.c.6547924.v1

Zobrazit plný text záznamu

Supplementary Data Table S1 from Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response

Characteristics of patients in the real-world clinico-genomic cohort

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d04d6516cd719ccacceafa013677769
https://doi.org/10.1158/2159-8290.22535713.v1

Zobrazit plný text záznamu

Data from Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer

Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal adenocarcinomas (PDAC). Using an inducible mouse model of KRAS*-driven PDAC, we compared KRAS* genetic extinction with pharmacologic inhibition of MEK1 in tumor spheres

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e6cc3de94177d6cceaf6f5a7a969c7b
https://doi.org/10.1158/0008-5472.c.6507350

Zobrazit plný text záznamu

supplementary Figures S1-S10 from Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer

supplementary Figures S1-S10. S1 growth and regression of iKRAS tumors. S2 culture comparison. S3 immunohistochemistry of p-erk and p-s6 S4 Phospho rtk array S5 Validation of anti AXL antibodies S6 validationn of the AXL inhibitor in vitro S7 validat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ed0e9df79b92edf0079fefd91c553a5
https://doi.org/10.1158/0008-5472.22407623.v1

Zobrazit plný text záznamu